

ACCESS TO MEDICINES

IN THE OFF-PATENT SECTOR

Medicines for Europe - EPF Dialogue

MEDICINES FOR EUROPE

26/04/2017



medicines
for europe

better access. better health.



Medicines For Europe VISION



PATIENTS



QUALITY



VALUE



SUSTAINABILITY



PARTNERSHIP

Generic Medicines A Cornerstone of Healthcare Sustainability

KEY FIGURES ON GENERIC MEDICINES



56%
OF DISPENSED
MEDICINES

22% +
OF PHARMACEUTICAL EXPENDITURES



-€100BN
LESS SPENDING
THROUGH GENERIC COMPETITION

+350 
MANUFACTURING SITES
IN THE EU



HIGH QUALITY MEDICINES
TO OVER
500 MILLIONS
PATIENTS

Cardiovascular | Hypertension
Diabetes | Depression
Epilepsy | Mental disorder
Gastro-intestinal



+100% PATIENT ACCESS
OVER 10 YEARS

+160,000
EMPLOYEES




UP TO
17%
R&D INVESTMENT
OF TURNOVER



Still considerable opportunities to increase uptake throughout Europe

Protected and off-patent marked share (volume) by country, June 2015




Generic medicines increase patient access



Twice as many patients treated... without an impact on treatment costs

Evolution of volume, price and treatment cost in seven therapy areas



THE EVIDENCE THAT THE ROOT CAUSE OF MEDICINES SHORTAGES ARE ECONOMIC, INCLUDING UNSUSTAINABLE P&R POLICIES, IS OVERWHELMING



Study



Proximate Causes

**Kweder
2013**

“It is time for health-care systems to recognize that such costs and economic drivers are essential elements”

**De
Weerdt
2015**

“For generic medicines, internal or external reference pricing, tendering as well as price capping may affect drug shortages”

**Pauwels
2014**

“Beyond pure manufacturing problems related to technical issues or quality problems and can also involve economic factors”

**Pauwels
2015**

“For generic medicines, internal or external reference pricing, tendering as well as price capping may affect drug shortages”

TACKLING SHORTAGES

IN THE OFF-PATENT SECTOR

- Healthy competition policies **can prevent medicines shortages**
- Price cuts and increasing regulatory costs make it difficult to **introduce or maintain generic products in the market**
- Aligned communication between authorities and manufacturers can help to **prevent shortages**
- **Continuous dialogue between key stakeholders** to validate solutions is required





References

- Alevizakos M, Detsis M, Grigoras CA, et al. The Impact of Shortages on Medication Prices: Implications for Shortage Prevention. *Drugs*. 2016;76(16):1551-8.
- Barlas S. FDA strategies to prevent and respond to drug shortages: finding a better way to predict and prevent company closures. *P & T : a peer-reviewed journal for formulary management*. 2013;38(5):261-3.
- Birgli. An Evaluation of Medicines Shortages in Europe with a more in-depth review of these in France, Greece, Poland, Spain, and the United Kingdom. Zug: Birgli, 2013. Available from: <http://static.correofarmaceutico.com/docs/2013/10/21/evaluation.pdf>.
- Bogaert P, Prokop A, Bochenek T. Prevention and Management of Medicine Shortages in Belgium, France and from The Perspective of the European Union. *Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research*. 2014;17(7):A412.
- De Weerd E, Simoens S, Hombroeckx L, et al. Causes of drug shortages in the legal pharmaceutical framework. *Regulatory toxicology and pharmacology : RTP*. 2015;71(2):251-8.
- Gagnon 2012. Drug Shortages: Searching for a Cure *Healthcare policy Vol.7 No.4, 2012*
- Griffith MM, Gross AE, Sutton SH, et al. The impact of anti-infective drug shortages on hospitals in the United States: trends and causes. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2012;54(5):684-91.
- Hassig TB, McKinzie BP, Fortier CR, et al. Clinical management strategies and implications for parenteral nutrition drug shortages in adult patients. *Pharmacotherapy*. 2014;34(1):72-84.
- Holtorf AP, Rinde H, Maniadakis N. Drug shortages in Europe and the USA: The underlying reasons and consequences. *ISPOR 15th Annual European Congress; 10th February 2017; Berlin, Germany: Presented at the ISPOR 15th Annual European Congress (Berlin, 5 November 2012); 2012*.
- Iyengar S, Hedman L, Forte G, et al. Medicine shortages: a commentary on causes and mitigation strategies. *BMC medicine*. 2016;14(1):124.
- Kaposy C. Drugs, money, and power: the Canadian drug shortage. *Journal of bioethical inquiry*. 2014;11(1):85-9.
- Kweder SL, Dill S. Drug shortages: the cycle of quantity and quality. *Clinical pharmacology and therapeutics*. 2013;93(3):245-51.
- Lipworth W, Kerridge I. Why drug shortages are an ethical issue. *The Australasian medical journal*. 2013;6(11):556-9.
- Markowski ME. *Drug Shortages: The Problem of Inadequate Profits*. Cambridge, MA: Harvard Law School, 2012. Available from: <https://dash.harvard.edu/handle/1/11940215>.
- Mazer-Amirshahi M, Hawley KL, Zocchi M, et al. Drug shortages: Implications for medical toxicology. *Clinical toxicology (Philadelphia, Pa)*. 2015;53(6):519-24.
- McKeever AE, Bloch JR, Bratic A. Drug shortages and the burden of access to care: a critical issue affecting patients with cancer. *Clinical journal of oncology nursing*. 2013;17(5):490-5.
- Morrison A. *Drug Supply Disruptions [Environmental Scan Issue 17]*. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2011. Available from: https://www.cadth.ca/media/pdf/Drug_Supply_Disruptions_es-18_e.pdf.
- Pauwels K, Huys I, Casteels M, et al. Drug shortages in European countries: a trade-off between market attractiveness and cost containment? *BMC health services research*. 2014;14:438.
- Pauwels K, Simoens S, Casteels M, et al. Insights into European drug shortages: a survey of hospital pharmacists. *PloS one*. 2015;10(3):e0119322.
- Ramanan S, Grampp G. Preventing shortages of biologic medicines. *Expert review of clinical pharmacology*. 2014;7(2):151-9.
- Reed BN, Fox ER, Konig M, et al. The impact of drug shortages on patients with cardiovascular disease: causes, consequences, and a call to action. *American heart journal*. 2016;175:130-41.
- Rider AE, Templett DJ, Daley MJ, et al. Clinical dilemmas and a review of strategies to manage drug shortages. *Journal of pharmacy practice*. 2013;26(3):183-91.
- Woodcock J, Wosinska M. Economic and technological drivers of generic sterile injectable drug shortages. *Clinical pharmacology and therapeutics*. 2013;93(2):170-6.
- Yurukoglu AL, E. Ridley D.B. *The Role of Government Reimbursement in Drug Shortages*. US: Stanford University, 2016. Available from: <https://web.stanford.edu/~ayurukog/shortages.pdf>.